AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
2 Department of Hematology, Liquan Hospital, GoBroad Medical Institute of Hematology (Shanghai Center), shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China, Wuhan, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
ABSTRACT
Background
Letermovir prophylaxis has transformed cytomegalovirus (CMV) prevention after haploidentical hematopoietic cell transplantation (HCT); however, fixed-duration prophylaxis does not account for substantial heterogeneity in post-transplant antiviral immune recovery. Breakthrough clinically significant CMV infection (cs-CMVi) remains a major challenge after prophylaxis discontinuation. Whether immune reconstitution kinetics can enable individualized CMV risk stratification and prevention remains unknown.
Methods
We retrospectively analyzed 304 adult CMV-seropositive patients with hematologic malignancies undergoing first haploidentical HCT who received letermovir prophylaxis for up to 100 days between September 2022 and May 2026. Patients were categorized according to donor CMV serostatus as donor-seronegative/recipient-seropositive (D−/R+; n = 40) or donor-seropositive/recipient-seropositive (D+/R+; n = 264). CMV-CMI was measured by CMV enzyme-linked immunospot (CMV-ELISpot), reconstitution was defined as IE-1 ≥ 50 and/or pp65 ≥ 100 spot-forming cells per 2.5×106 PBMCs, CMV-CMI testing covered 55.0% (22/40) and 68.7% (181/264) of patients in D−/R+ and D+/R+ groups, respectively. The primary endpoint was 1-year cumulative incidence of cs-CMVi. Secondary endpoints included CMV-CMI recovery kinetics, cs-CMVi by day 100 and from day 100 to 1 year, CMV disease, refractory/resistant (R/R) CMV infection, and time to CMV-CMI reconstitution. Cumulative incidence analyses, multivariable cause-specific Cox models, propensity-score matching, and time-dependent analyses were performed to determine clinical and immunological determinants of CMV risk.
Results
Among 304 recipients, baseline clinical characteristics were balanced between groups, although donors in the D−/R+ group were younger (median 16 vs. 27 years; P < .001). After a median follow-up of 580 (IQR, 350–922) days among survivors, the 1-year cumulative incidence of cs-CMVi was significantly higher in D−/R+ than D+/R+ recipients (37.3% [95% CI:21.2–53.0] vs. 18.2% [95% CI:13.4–23.1]; P = .033). The excess risk occurred predominantly after letermovir discontinuation, with higher cs-CMVi incidence from day 100 to 1 year (30.0% vs. 14.0%; P = .020). CMV-CMI recovery was delayed in D−/R+ recipients (median 270 vs. 150 days; P = .017), with fewer patients achieving CMV-CMI reconstitution by day 100 (17.5% vs. 39.0%; P = .011).
Importantly, CMV-CMI recovery dynamically predicted subsequent CMV protection. In a day-90 landmark analysis, recipients with CMV-CMI reconstitution had fewer subsequent cs-CMVi events (9/97 vs. 31/178; P = .033). In time-dependent Cox analysis adjusting for donor CMV serostatus and donor age, durable CMV-CMI reconstitution established ≥ 60 days before CMV events was independently associated with reduced cs-CMVi risk (aHR 0.36; 95% CI: 0.14–0.94; P = .036). Donor CMV seronegativity remained independently associated with cs-CMVi (aHR 3.02; P = .001). Propensity-score matching confirmed higher cs-CMVi incidence in D−/R+ recipients (36.1% vs 10.5%; P=.011).
Conclusions
In the letermovir era, CMV prevention after haploidentical HCT remains limited by heterogeneity in immune recovery. Donor CMV seronegativity identifies recipients with delayed CMV-specific immune reconstitution, whereas durable CMV-CMI recovery provides independent protection against breakthrough CMV infection. These findings establish an immune reconstitution-guided framework for risk-adapted CMV prevention and support prospective evaluation of CMV-CMI-guided prophylaxis strategies after transplantation.
DISCLOSURES
Luxiang Wang: No relevant conflicts of interest to declare.